2023
PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy.
Wong Zhun Hong N, Zhao J, Zhu K, Yap D, Kumarakulasinghe N, Huang Y, Sundar R. PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy. Journal Of Clinical Oncology 2023, 41: e21140-e21140. DOI: 10.1200/jco.2023.41.16_suppl.e21140.Peer-Reviewed Original ResearchNon-small cell lung cancerPD-L1 expressionFirst-line chemotherapyNon-squamous non-small cell lung cancerSquamous non-small cell lung cancerTreated with first-line chemotherapyPhase III randomized trialNegative predictive biomarkerNon-squamous histologyPD-L1 subgroupsPD-L1Tumor progressionSquamous histologyPredictive biomarkersKaplan-MeierAdvanced squamous non-small cell lung cancerAdvanced non-small cell lung cancerPatients treated with first-line chemotherapyRandomized trialsInvestigated PD-L1 expressionRisk of tumor progressionHigh PD-L1Kaplan-Meier (KM) curvesPositive predictive biomarkerImmune checkpoint inhibition
2022
Pan-immune-inflammation value as a predictive biomarker for survival in advanced non-small cell lung cancer patients treated with immunotherapy.
Sooi K, Low J, Miow Q, Kumarakulasinghe N, Sundar R, Huang Y. Pan-immune-inflammation value as a predictive biomarker for survival in advanced non-small cell lung cancer patients treated with immunotherapy. Journal Of Clinical Oncology 2022, 40: e21095-e21095. DOI: 10.1200/jco.2022.40.16_suppl.e21095.Peer-Reviewed Original ResearchPan-immune-inflammation valueNon-small cell lung cancerProgression-free survivalAdvanced non-small cell lung cancerNon-small cell lung cancer patientsPD-L1Overall survivalPrognostic factorsPredictive biomarkersUnivariate analysisAdvanced non-small cell lung cancer patientsHigher PIVMedian progression-free survivalMultivariate analysisImmune checkpoint inhibitor therapyPredictor of survival outcomesCell lung cancer patientsPredictive valueImmune checkpoint inhibitorsPD-L1 statusAdvanced NSCLC patientsCheckpoint inhibitor therapyTreated with immunotherapyANCA-associated vasculitisECOG performance status
2021
Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
Low J, Huang Y, Sooi K, Ang Y, Chan Z, Spencer K, Jeyasekharan A, Sundar R, Goh B, Soo R, Yong W. Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer. International Journal Of Cancer 2021, 149: 169-176. PMID: 33634869, PMCID: PMC9545741, DOI: 10.1002/ijc.33534.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerProgression-free survivalCell lung cancerFood and Drug AdministrationOverall survivalTreatment of advanced non-small cell lung cancerLung cancerDose of pembrolizumabImmune-related toxicitiesEffectiveness of pembrolizumabWeight-based dosingRetrospective observational studyNational University HospitalDegrees of cost savingsCost-minimisation analysisFixed doseSurvival outcomesAsian patientsNo significant differencePembrolizumabOncogenic driversSingle agentLow dosesRandomised trials
2020
Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
Low J, Sooi K, Huang Y, Chan G, Ang Y, Chong W, Tan H, Ngoi N, Choo J, Lee M, Muthu V, Asokumaran Y, Walsh R, Wong R, Chan Z, Soo R, Sundar R, Yong W. Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia. Journal Of Clinical Oncology 2020, 38: e19385-e19385. DOI: 10.1200/jco.2020.38.15_suppl.e19385.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerProgression free survivalFree survivalFixed doseTreatment of non-small cell lung cancer patientsOncogenic driversNon-small cell lung cancer patientsTreatment of non-small cell lung cancerCell lung cancer patientsResponse rateTreated with pembrolizumabDose of pembrolizumabEfficacy of pembrolizumabKaplan Meier methodUS Food and Drug AdministrationSurvival of patientsCell lung cancerLow dose groupLung cancer patientsNational University HospitalFood and Drug AdministrationStandard of careECOG 0Overall survival
2017
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Sundar R, Chénard-Poirier M, Collins D, Yap T. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers In Medicine 2017, 4: 39. PMID: 28443282, PMCID: PMC5385461, DOI: 10.3389/fmed.2017.00039.Peer-Reviewed Educational MaterialsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerClinical outcome of advanced non-small cell lung cancerOutcomes of advanced non-small cell lung cancerManagement of advanced non-small cell lung cancerLung cancerPrecision medicineEra of precision medicineClinical trial testingImpact of precision medicineDriver aberrationsClinical outcomesNon-smallAntitumor therapyRegulatory approvalMultiple deficienciesCancerHypothesis-testing studiesDiseaseComplex diseasesMedicineTherapyPatients